1 / 2

Influenza Vaccine Market Size & Share

Influenza Vaccine Market

Anjali228
Download Presentation

Influenza Vaccine Market Size & Share

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Influenza Vaccine Market Analysis Market Size & Growth The global influenza vaccine market is projected to grow from $8.55 billion in 2024 to $17.77 billion by 2032, at a CAGR of 9.6%. North America dominates with a 53.7% market share in 2023, valued at $4.28 billion. Key Market Drivers  Rising disease prevalence: WHO reports 3-5 million severe influenza cases annually, causing 290,000-650,000 deaths globally  Government support: Expanding immunization programs and public health campaigns  R&D investments: Development of combination vaccines and new technologies  COVID-19 impact: Increased vaccine awareness and uptake during pandemic Market Segments By Type  Inactivated vaccines lead with 91.94% market share in 2023  Live attenuated vaccines growing at slower rate due to development challenges  mRNA vaccines emerging as promising segment with new developments By Distribution Channel  Hospital & retail pharmacies: 54% market share in 2023  Government suppliers  Others Regional Analysis North America  Largest market share (53.35%) in 2023  Strong public health infrastructure  High vaccination rates  Presence of major manufacturers Europe  Second-largest market position  Strong healthcare infrastructure  Recent developments include GSK's agreement with HERA for 85 million pandemic vaccine doses Asia Pacific

  2. Fastest-growing region  Large population base  Increasing healthcare expenditure  Rising government initiatives Key Players 1.GSK plc 2.Sanofi 3.AstraZeneca 4.CSL Limited 5.SINOVAC Recent Developments  June 2024: SINOVAC announced $100 million investment in Brazil for vaccine production  April 2024: CDC expanded RSV vaccine recommendations for adults aged 50-59  February 2024: CSL and Arcturus received EU approval for KOSTAIVE mRNA COVID-19 vaccine3 Market Challenges  Extended vaccine production timelines (10-15 years average)  Complex regulatory requirements  High manufacturing costs  Cold chain storage requirements Report- Fortune Business Insights - Influenza Vaccine Market Size & Share | Industry Growth, 2032 https://www.fortunebusinessinsights.com/industry-reports/influenza-vaccine-market-101896

More Related